Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Lupus Erythematosus, Systemic

• A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants
• A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
• SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
• A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intol
• Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
• JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
• Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
• Efficacy and Safety of Telitacicept in Early SLE
• A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
• A Study of CC-97540 in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE)
• A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
• Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
• A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
• Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
• A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
• Anti-CD20 Antibodies for Treatment of SLE-PAH
• Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
• An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Autoimmune Disorders
• A Clinical Study of MIL62 in Systemic Lupus Erythematosus
• Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
• A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
• Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
• A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
• Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
• A Study of DS-7011a in Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
• The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN
• Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)
• Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
• A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
• A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
• Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus
• The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
• A Study to Assess the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolera
• Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE)
• Probiotics in Systemic Lupus Erythematosus
• Vitamin D and Curcumin Piperine Attenuates Disease Activity and Cytokine Levels in Systemic Lupus Erythematosus Patients
• A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
• Progressive Resisted Exercise Plus Aerobic Exercise on Osteoporotic Systemic Lupus Erythmatosus
• Efficacy and Safety of Topical Nicotinamide in Treatment of Discoid Lupus Erythematosus
• A Study to Evaluate the Continuous Safety and Efficacy of BIIB059 in Adults With Active Systemic Lupus Erythematosus
• Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
• Study of CUG252 in Healthy Volunteers and in Patients With Systemic Lupus Erythematosus
• Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
• Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
• A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants
• Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus
• Effect of Vitamin D Supplement on Disease Activity in SLE
• Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
• A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
• Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
• The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
• A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus
• A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
• Autologous Stem Cell Transplantation: International Lupus Trial
• Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus
• Tofacitinib in Prevention of Photosensitivity in Lupus
• Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus
• Safety Tolerability and Pharmacokinetics of Oral LABP-104 in Healthy Adult Male and Female Volunteers
• Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's or SLE
• COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
• A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
• Belimumab In Treatment of Early Systemic Lupus Erythematosus
• Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
• A Phase 2 of VIB7734 for the Treatment of Moderate to Severely Active SLE
• Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)
• Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
• A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
• A Model About the Response of Belimumab in SLE
• A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
• Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
• A Study to Evaluate Efficacy and Safety of BMS-986165 in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
• ALPN-101 in Systemic Lupus Erythematosus
• An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus
• Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)
• Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
• Sirolimus Treatment Of Patients With SLE
• Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
• Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
• A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus
• Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
• Study of M5049 in CLE and SLE Participants
• Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
• A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
• Centrally Acting ACE Inhibition in SLE
• A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
• Sequential Belimumab and T-cell Based Therapy in SLE
• A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
• The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases
• A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
• The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus
• Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants
• Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells
• Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
• Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
• Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus
• Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial
• A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus
• Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
• Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus
• A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
• Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
• Effect of Curcumin on Systemic Lupus Erythematosus
• Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
• Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects
• A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
• Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
• Mesenchymal Stromal Cells (MSC´s) in Renal Lupus
• Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
• A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
• A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
• A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
• Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus
• BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)
• Synergetic B-cell Immunomodulation in SLE - 2nd Study.
• Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
• A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
• RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
• Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
• Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
• A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)
• An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects
• Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
• A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
• CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus
• Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
• An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
• Exploratory Study of DHA in Systemic Lupus Erythematosus Patients
• A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
• Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
• MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE
• Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
• A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
• Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus
• Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus
• The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients
• Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus
• A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
• An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
• A Phase I Study of ICP-022 in Healthy Subjects
• Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
• A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
• Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
• Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
• A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
• JBT-101 in Systemic Lupus Erythematosus (SLE)
• Rituximab Objective Outcome Measures Trial in SLE
• Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous
• Study of Anti-Malarials in Incomplete Lupus Erythematosus
• A Phase II Study of M2951 in SLE
• A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
• ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
• Acthar Gel for Active Systemic Lupus Erythematosus (SLE)
• Anti-infection of Low-does IL-2 in SLE
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus
• A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
• Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus
• Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
• Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus
• A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
• Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
• Acthar SLE (Systemic Lupus Erythematosus)
• Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis
• The Effect of Metformin on Reducing Lupus Flares
• TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
• A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
• Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
• Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
• A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
• Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus
• MSC2364447C Phase 1b in Systemic Lupus Erythematosus
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
• Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
• CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
• A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
• 3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus
• Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
• A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus
• Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
• Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
• Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
• A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus
• Abatacept for SLE Arthritis (IM101-330)
• Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
• A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus
• A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
• A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
• Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
• Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients
• Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients
• Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous
• Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus
• Synergetic B-cell Immodulation in SLE
• Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
• A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
• Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects
• Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
• Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
• Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
• Low-dose IL-2( Interleukin-2) Treatment in SLE
• Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
• CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
• Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
• Nelfinavir in Systemic Lupus Erythematosus
• A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
• Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
• Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
• A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184
• Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
• ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
• Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
• Vitamin D to Improve Endothelial Function in SLE
• A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects
• Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
• The Effect of Calcitriol on Progress and Activity of Lupus Nephritis
• A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
• Phase Ib Study of SC Milatuzumab in SLE
• IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
• Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.
• Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
• An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184
• Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis
• Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus
• Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
• Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
• Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
• Omalizumab for Lupus
• Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus
• A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
• Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
• An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
• Safety Study of AMG 557 in Subjects With Lupus Arthritis
• Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
• Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
• WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)
• BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115
• Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
• Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
• Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.
• Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion
• Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
• Belimumab (BENLYSTA®) Pregnancy Registry
• Japanese phase1 Study of Belimumab (IV vs SC)
• On Open-Label Study in Participants With Systemic Lupus Erythematosus
• A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
• Zostavax in Systemic Lupus Erythematosus
• A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
• Atacicept Demonstrating Dose RESponSe
• The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE)
• Vitamin D Supplementation in Systemic Lupus Erythematosus
• Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
• Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
• CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus
• Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)
• The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients
• Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
• GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
• Evaluation of the Influence of Food Regimen on Oshadi D Absorption
• Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus
• A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
• To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
• Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus
• Levothyroxine in Pregnant SLE Patients
• Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus
• Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
• Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
• GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
• A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus
• A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
• A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
• A Trial of Rosuvastatin in Systemic Lupus Erythematosus
• Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
• PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
• A Study to Evaluate the Efficacy and Safety of CEP-33457 in Patients With Systemic Lupus Erythematosus
• Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations
• Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)
• Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
• Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis
• Auto-immunity in Lupus Patients After Influenza Vaccine
• Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
• A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.
• An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)
• Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)
• Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
• A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis
• NOX-E36 First-in-Human (FIH) Study
• Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study
• A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
• An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)
• Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study
• Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level
• Efficacy of Fish Oil in Lupus Patients
• Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis
• Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
• The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus
• Prospective Study of Rapamycin for the Treatment of SLE
• Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
• A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
• Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
• Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus
• Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)
• Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
• Aspirin Resistance in Systemic Lupus Erythematosus (SLE)
• Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
• A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
• Vitamin D3 in Systemic Lupus Erythematosus
• Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
• Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
• Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus
• A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus
• Leflunomide in Systemic Lupus Erythematosus
• Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
• A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
• Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions
• Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2)
• Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
• Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus
• Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
• FolateScan in Autoimmune Disease
• Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
• A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus
• A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
• Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors
• The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria
• Myfortic Versus Azathioprine in Systemic Lupus Erythematosus
• Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
• Sunscreen RV 2457C in Photoinduced CLE
• Study of Methotrexate in Lupus Erythematosus
• An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus
• Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
• A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
• Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)
• Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies
• The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS
• A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
• Sirolimus for Autoimmune Disease of Blood Cells
• Effect of Hormone Replacement Therapy on Lupus Activity
• Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome
• Study of LJP 394 (Abetimus Sodium) in Lupus Patients
• Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
• Study of Epratuzumab in Systemic Lupus Erythematosus
• A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
• Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus
• TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
• Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis
• Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)
• Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva
• Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil
• Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis
• Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)
• Cutaneous Lupus Erythematosus and Elidel
• A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus
• Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention
• Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease
• Memantine in Systemic Lupus Erythematosus
• A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
• Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
• Triptorelin for Ovary Protection in Childhood Onset Lupus
• Lupus Atherosclerosis Prevention Study
• Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
• Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
• Study of Epratuzumab in Systemic Lupus Erythematosus
• Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
• Study of LJP 394 in Lupus Patients With History of Renal Disease
• GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
• Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
• Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
• Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
• Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
• To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids
• Monoclonal Antibody Treatment for Systemic Lupus Erythematosus
• Study of GL701 in Men With Systemic Lupus Erythematosus
• Anti-CD20 in Systemic Lupus Erythematosus
• Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
• Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity
• Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
• Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus
• Humanized LL2IGG to Treat Systemic Lupus Erythematosus
• Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
• Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
• Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus
• Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
• High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide
• Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus
• Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus
• Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus
• A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
• Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
• Drug Therapy in Lupus Nephropathy
• Serologically Active, Clinically Stable Systemic Lupus Erythematosus
• Safety of Estrogens in Lupus: Birth Control Pills
• Safety of Estrogens in Lupus: Hormone Replacement Therapy